Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
Efficacy of anti-VEGF therapy for Irvine-Gass syndrome: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balsby Daniel, Arnold-Vangsted Andreas, Rosenørn Emil Alexander, Eriksen Nathalie Skovgaard, Ahmed Hassan Javed, Krarup Therese Grønhøj, Klefter Oliver Niels, Hajari Javad Nouri, Subhi Yousif, Schneider Miklos
Аннотация
PURPOSE: To investigate the efficacy of intravitreal anti-VEGF agents in the treatment of Irvine-Gass syndrome (IGS).
METHODS: Systematic review with meta-analysis. The primary outcome was the percentage with resolution of cystoid macular edema (CME). Secondary outcomes were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to time of follow-up. A meta-analysis was conducted on changes in BCVA and CMT from baseline to a 6-month follow-up visit.
RESULTS: Seven retrospective studies and one randomized, sham-controlled, multicenter study provided data on a total of 343 eyes of 334 patients. The primary outcome was reported too heterogeneously to allow for meta-analysis, but three studies reported resolution of CME during follow-up in 66.4% to 100% of eyes treated. At 6 months after treatment initiation, the mean improvement in BCVA was 0.65 (95%CI: -0.83; -0.47) logMAR, and the mean decrease in CMT was 290.41 (95%CI: -351.33; -229.54) µm.
CONCLUSION: Current literature suggests potential benefits of intravitreal anti-VEGF in treating IGS. However, its superiority over placebo remains uncertain, suggesting the need for randomized, placebo-controlled trials.
METHODS: Systematic review with meta-analysis. The primary outcome was the percentage with resolution of cystoid macular edema (CME). Secondary outcomes were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to time of follow-up. A meta-analysis was conducted on changes in BCVA and CMT from baseline to a 6-month follow-up visit.
RESULTS: Seven retrospective studies and one randomized, sham-controlled, multicenter study provided data on a total of 343 eyes of 334 patients. The primary outcome was reported too heterogeneously to allow for meta-analysis, but three studies reported resolution of CME during follow-up in 66.4% to 100% of eyes treated. At 6 months after treatment initiation, the mean improvement in BCVA was 0.65 (95%CI: -0.83; -0.47) logMAR, and the mean decrease in CMT was 290.41 (95%CI: -351.33; -229.54) µm.
CONCLUSION: Current literature suggests potential benefits of intravitreal anti-VEGF in treating IGS. However, its superiority over placebo remains uncertain, suggesting the need for randomized, placebo-controlled trials.